Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

STOK

Stoke Therapeutics Inc

Mar 20 • 04:00PM ET

33.51

+0.32 0.96 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT PTCT FOLD RARE NTLA CRSP EDIT ARWR VRTX ALNY

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO DFAS FDM

Index	RUT	P/E	-	EPS (ttm)	-0.15	Insider Own	22.07%	Shs Outstand	58.92M	Perf Week	0.96%
Market Cap	1.98B	Forward P/E	-	EPS next Y	-3.38	Insider Trans	-2.28%	Shs Float	46.10M	Perf Month	-2.50%
Enterprise Value	1.70B	PEG	-	EPS next Q	-0.93	Inst Own	105.51%	Short Float	26.90%	Perf Quarter	1.98%
Income	-6.89M	P/S	10.75	EPS this Y	94.65%	Inst Trans	11.12%	Short Ratio	17.21	Perf Half Y	42.60%
Sales	184.42M	P/B	5.60	EPS next Y	-3724.54%	ROA	-2.00%	Short Interest	12.40M	Perf YTD	5.58%
Book/sh	5.98	P/C	6.95	EPS next 5Y	-24.20%	ROE	-2.37%	52W High	40.22 -16.68%	Perf Year	302.28%
Cash/sh	4.82	P/FCF	44.14	EPS past 3/5Y	64.49% 40.50%	ROIC	-1.95%	52W Low	5.35 526.36%	Perf 3Y	310.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	145.89% -	Gross Margin	97.73%	Volatility	7.95% 7.31%	Perf 5Y	-30.04%
Dividend TTM	-	EV/Sales	9.22	EPS Y/Y TTM	94.17%	Oper. Margin	-11.16%	ATR (14)	2.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.28	Sales Y/Y TTM	404.50%	Profit Margin	-3.73%	RSI (14)	48.22	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.28	EPS Q/Q	-439.83%	SMA20	-4.67%	Beta	1.21	Target Price	45.10
Payout	-	Debt/Eq	0.01	Sales Q/Q	-93.80%	SMA50	2.39%	Rel Volume	2.79	Prev Close	33.19
Employees	170	LT Debt/Eq	0.00	Earnings	Nov 04 AMC	SMA200	34.11%	Avg Volume	720.68K	Price	33.51
IPO	Jun 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.40% 72.60%	Trades		Volume	2,008,354	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-26	Initiated	Wolfe Research	Outperform	$40
Feb-05-26	Initiated	Guggenheim	Buy	$60
Jan-05-26	Resumed	Chardan Capital Markets	Buy	$35
Jul-18-25	Initiated	Jefferies	Buy	$30
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$24
Oct-14-24	Resumed	Leerink Partners	Outperform	$18
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral	$9 → $12
Apr-26-23	Resumed	Canaccord Genuity	Buy	$24
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$22 → $9
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$30
Jan-31-22	Initiated	Jefferies	Buy	$50
Dec-03-21	Initiated	BofA Securities	Buy	$43
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight	$41
May-18-21	Initiated	UBS	Neutral	$35
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform	$58
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral

Show Previous Ratings

Mar-17-26 05:12PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -5.63%
Mar-05-26 08:44AM	Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? (Zacks)
Mar-04-26 05:06PM	The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome (Business Wire)
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-24-26 04:01PM	Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
12:59PM	Loading…
Feb-23-26 12:59PM	This Rare Disease Biotech Name Teases Around A Buy Point (Investor's Business Daily) +5.66%
Feb-18-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +10.94%
Feb-15-26 10:03AM	Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit (MarketBeat)
Feb-11-26 07:30AM	Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Feb-04-26 04:01PM	Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire) -5.30%
Jan-27-26 02:05PM	Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA (PR Newswire)
Jan-16-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-11-26 02:00PM	Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome (Business Wire)
Jan-06-26 04:01PM	Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +8.20%
Dec-16-25 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
01:16PM	Loading…
01:16PM	Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% (Investor's Business Daily)
Dec-01-25 07:30AM	Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-18-25 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +7.31%
Nov-17-25 07:30AM	Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments (Business Wire)
Nov-05-25 04:01PM	Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference (Business Wire) -9.94%
12:00PM	All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy (Zacks)
12:05AM	Stoke Therapeutics Inc (STOK) Q3 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Nov-04-25 06:00PM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-30-25 04:30PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates (Business Wire) -5.24%
Oct-20-25 07:30AM	Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Oct-19-25 03:09AM	H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK) (Insider Monkey)
Oct-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Oct-10-25 10:06AM	Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
04:30PM	Loading…
Oct-09-25 04:30PM	Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
09:25AM	Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 07:30AM	Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer (Business Wire)
06:07AM	Gilead delays arrival of Biktarvy copycats; CDC updates vaccine schedule (BioPharma Dive)
Sep-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Sep-05-25 04:16PM	ZoomInfo, International Money Express, and More Stocks See Action From Activist Investors (Barrons.com) +5.35% +6.33%
Sep-02-25 07:00AM	Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
Aug-28-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 (Business Wire)
Aug-25-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (Business Wire)
Aug-18-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-13-25 03:12AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... (GuruFocus.com) +24.98%
Aug-12-25 05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
06:38AM	First patient dosed in Phase III trial of zorevunersen for Dravet syndrome (Clinical Trials Arena)
Aug-11-25 09:26AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:00AM	Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (GlobeNewswire)
Aug-07-25 07:00AM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates (Business Wire)
Aug-06-25 04:30PM	Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Aug-05-25 06:35PM	Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 10:17AM	Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug (Investing.com) +7.04%
Jul-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-10-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (GlobeNewswire)
Jun-17-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-25 07:30AM	Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-16-25 09:55AM	Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet (Zacks)
May-13-25 09:50AM	Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates (Zacks) -7.56%
07:00AM	Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
May-12-25 06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-01-25 12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:28AM	Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? (Investor's Business Daily)
06:45AM	Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar (Investor's Business Daily)
Apr-28-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-25 06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-22-25 12:00PM	Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.08%
04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-01-25 04:30PM	Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -6.32% +5.94%
Mar-18-25 12:40PM	Stoke Therapeutics Stock Slips as CEO Steps Down (Investopedia)
12:40PM	Stoke Therapeutics Slips as CEO Steps Down (Investopedia)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:05AM	Stoke CEO exits; Medicare drug price talks advance (BioPharma Dive)
07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Business Wire)
06:58AM	Stoke Therapeutics Announces CEO Transition (Business Wire)
Mar-17-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-26-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-19-25 06:55AM	Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (Pharmaceutical Technology)
Feb-18-25 01:32PM	Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (Benzinga) -9.08%
08:00AM	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (Business Wire)
07:25AM	Biogen buys rights to Stokes rare epilepsy drug (BioPharma Dive)
Feb-05-25 08:51AM	Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? (Zacks)
Jan-08-25 04:30PM	Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
06:31AM	Tenvie raises $200M for brain drug R&D; Sana spikes on single patients results (BioPharma Dive)
Jan-07-25 07:00AM	Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) -15.52%
Jan-06-25 04:30PM	Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome (Business Wire)
Dec-06-24 12:00PM	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) +5.57%
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 07:00AM	Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome (Business Wire) +12.07%
Dec-02-24 08:00AM	Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting (Business Wire)
Nov-26-24 01:56AM	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond (Pharma Voice)
Nov-20-24 09:55AM	Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-08-24 09:55AM	Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade (Zacks)
Nov-05-24 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire)
Oct-29-24 10:01AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-12-24 06:10PM	Stoke Therapeutics assumed with an Outperform at Leerink (TipRanks)
10:18AM	Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases (Insider Monkey)
Sep-23-24 07:07PM	Skorpios Trust Reduces Stake in Stoke Therapeutics Inc (GuruFocus.com)

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JONATHAN ALLAN	Officer	Mar 20 '26	Proposed Sale	33.19	9,293	308,435		Mar 20 04:33 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Option Exercise	2.19	1,365	2,989	42,163	Mar 19 06:01 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 18 '26	Sale	31.34	6,686	209,569	40,798	Mar 19 06:01 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 17 '26	Sale	33.01	6,164	203,451	47,484	Mar 19 06:01 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Sale	29.99	1,461	43,815	40,702	Mar 19 06:01 PM
Leggett Thomas	Chief Financial Officer	Mar 18 '26	Sale	31.34	2,382	74,663	10,172	Mar 19 06:00 PM
Leggett Thomas	Chief Financial Officer	Mar 17 '26	Sale	33.01	2,196	72,482	12,554	Mar 19 06:00 PM
Hoitt Jason	Chief Patient Officer	Mar 18 '26	Sale	31.34	1,931	60,526	10,276	Mar 19 05:58 PM
Hoitt Jason	Chief Patient Officer	Mar 17 '26	Sale	33.01	1,781	58,785	12,207	Mar 19 05:58 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 18 '26	Sale	31.34	4,628	145,063	28,836	Mar 19 05:57 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 17 '26	Sale	33.01	4,267	140,838	33,464	Mar 19 05:57 PM
BARUCH S. TICHO	Officer	Mar 19 '26	Proposed Sale	31.02	1,461	45,320		Mar 19 04:19 PM
Hoitt Jason	Chief Patient Officer	Mar 15 '26	Option Exercise	0.00	10,000	0	13,988	Mar 17 05:26 PM
Leggett Thomas	Chief Financial Officer	Mar 15 '26	Option Exercise	0.00	14,750	0	14,750	Mar 17 05:26 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '26	Option Exercise	0.00	33,850	0	53,648	Mar 17 05:25 PM
Kaye Edward M. MD	Director	Mar 15 '26	Option Exercise	0.00	61,750	0	110,874	Mar 17 05:24 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '26	Option Exercise	0.00	25,475	0	37,731	Mar 17 05:23 PM
LEVIN ARTHUR A	Director	Mar 13 '26	Sale	36.80	605	22,264	4,237	Mar 17 05:23 PM
ARTHUR A LEVIN	Director	Mar 13 '26	Proposed Sale	36.48	605	22,070		Mar 13 04:19 PM
TZIANABOS ARTHUR	Interim Executive Chair	Mar 10 '26	Option Exercise	8.33	3,955	32,945	35,694	Mar 12 04:57 PM
TZIANABOS ARTHUR	Interim Executive Chair	Mar 10 '26	Sale	40.00	4,355	174,214	31,339	Mar 12 04:57 PM
Krainer Adrian R.	Director	Mar 10 '26	Sale	39.74	33,243	1,320,964	283,302	Mar 12 04:56 PM
ARTHUR TZIANABOS	Director	Mar 10 '26	Proposed Sale	38.31	90,508	3,467,361		Mar 10 04:39 PM
Krainer Adrian R.	Director	Mar 02 '26	Sale	39.66	7,229	286,715	316,545	Mar 04 04:28 PM
Adrian Krainer	Director	Mar 02 '26	Proposed Sale	36.41	40,472	1,473,586		Mar 02 04:42 PM
LEVIN ARTHUR A	Director	Dec 31 '25	Option Exercise	0.00	1,211	0	4,842	Jan 05 04:16 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 08 '25	Sale	32.28	3,978	128,411	11,831	Dec 10 04:24 PM
Kaye Edward M. MD	Director	Dec 08 '25	Sale	32.27	13,430	433,385	49,124	Dec 10 04:23 PM
EDWARD M KAYE	Director	Dec 08 '25	Proposed Sale	30.87	13,430	414,584		Dec 08 04:40 PM
JONATHAN ALLAN	Officer	Dec 08 '25	Proposed Sale	30.87	3,978	122,801		Dec 08 04:38 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '25	Option Exercise	0.00	10,000	0	25,156	Dec 05 08:51 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 05 '25	Sale	31.34	3,662	114,762	19,798	Dec 05 08:51 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 04 '25	Sale	30.87	1,696	52,353	23,460	Dec 05 08:51 PM
Kaye Edward M. MD	Director	Dec 03 '25	Option Exercise	0.00	26,250	0	77,555	Dec 05 08:50 PM
Kaye Edward M. MD	Director	Dec 05 '25	Sale	31.32	8,548	267,761	62,554	Dec 05 08:50 PM
Kaye Edward M. MD	Director	Dec 04 '25	Sale	30.87	6,453	199,197	71,102	Dec 05 08:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '25	Option Exercise	0.00	6,000	0	25,612	Dec 05 08:49 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 05 '25	Sale	31.29	8,785	274,898	15,809	Dec 05 08:49 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 04 '25	Sale	30.87	1,018	31,425	24,594	Dec 05 08:49 PM
EDWARD M KAYE	Director	Dec 05 '25	Proposed Sale	31.05	2,181	67,720		Dec 05 04:38 PM
JONATHAN ALLAN	Officer	Dec 05 '25	Proposed Sale	31.05	7,781	241,600		Dec 05 04:29 PM
BARUCH TICHO	Officer	Dec 05 '25	Proposed Sale	31.05	1,989	61,758		Dec 05 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 01 '25	Option Exercise	0.00	11,981	0	19,176	Dec 03 08:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '25	Sale	30.65	2,014	61,725	15,156	Dec 03 08:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '25	Sale	29.78	2,006	59,743	17,170	Dec 03 08:23 PM
Kaye Edward M. MD	Director	Dec 03 '25	Sale	30.65	1,070	32,793	51,305	Dec 03 08:22 PM
Kaye Edward M. MD	Director	Dec 02 '25	Sale	29.78	1,066	31,748	52,375	Dec 03 08:22 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 01 '25	Option Exercise	0.00	12,357	0	24,188	Dec 03 08:20 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '25	Sale	30.65	2,292	70,245	19,612	Dec 03 08:20 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 02 '25	Sale	29.78	2,284	68,023	21,904	Dec 03 08:20 PM
Krainer Adrian R.	Director	Nov 24 '25	Sale	29.72	40,472	1,202,719	323,774	Nov 26 04:06 PM
Adrian Krainer	Director	Nov 24 '25	Proposed Sale	29.34	40,472	1,187,448		Nov 24 04:24 PM
Krainer Adrian R.	Director	Nov 14 '25	Sale	26.98	40,472	1,092,058	364,246	Nov 18 04:22 PM
Adrian Krainer	Director	Nov 14 '25	Proposed Sale	26.07	40,472	1,055,105		Nov 14 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 03 '25	Sale	25.72	5,931	152,566	7,195	Nov 05 04:20 PM
BARUCH TICHO	Officer	Nov 03 '25	Proposed Sale	30.04	5,931	178,167		Nov 03 04:22 PM
Kaye Edward M. MD	Director	Oct 08 '25	Option Exercise	0.60	25,000	15,000	74,124	Oct 10 04:12 PM
Kaye Edward M. MD	Director	Oct 08 '25	Sale	30.00	25,000	750,000	49,124	Oct 10 04:12 PM
EDWARD M KAYE	Director	Oct 08 '25	Proposed Sale	27.31	25,000	682,750		Oct 08 04:20 PM
Kaye Edward M. MD	Director	Oct 03 '25	Sale	25.09	42,461	1,065,206	49,124	Oct 07 04:26 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Oct 03 '25	Option Exercise	9.15	10,000	91,500	21,831	Oct 07 04:26 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Oct 03 '25	Sale	25.07	10,000	250,650	11,831	Oct 07 04:26 PM
EDWARD M KAYE	Director	Oct 03 '25	Proposed Sale	24.82	42,461	1,053,882		Oct 03 04:35 PM
JONATHAN ALLAN	Officer	Oct 03 '25	Proposed Sale	24.82	10,000	248,200		Oct 03 04:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '25	Sale	23.64	5,343	126,316	13,126	Oct 03 04:25 PM
LEVIN ARTHUR A	Director	Sep 30 '25	Option Exercise	0.00	1,211	0	3,631	Oct 01 04:47 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 02 '25	Sale	19.87	5,501	109,325	18,469	Sep 03 05:53 PM
Kaye Edward M. MD	Director	Sep 03 '25	Sale	20.13	45,996	925,858	91,585	Sep 03 05:51 PM
Kaye Edward M. MD	Director	Sep 02 '25	Sale	20.14	14,860	299,260	137,581	Sep 03 05:51 PM
Kaye Edward M. MD	Director	Aug 29 '25	Sale	20.00	1,029	20,580	152,441	Sep 03 05:51 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 02 '25	Option Exercise	7.07	9,150	64,690	33,098	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 29 '25	Option Exercise	7.07	850	6,010	24,798	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 02 '25	Sale	20.14	14,922	300,492	18,176	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 03 '25	Sale	20.07	6,345	127,317	11,831	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 29 '25	Sale	20.00	850	17,000	23,948	Sep 03 05:50 PM
BARUCH TICHO	Officer	Sep 02 '25	Proposed Sale	19.76	10,844	214,277		Sep 02 04:37 PM
EDWARD M KAYE	Director	Aug 29 '25	Proposed Sale	19.77	61,885	1,223,466		Aug 29 04:17 PM
JONATHAN ALLAN	Officer	Aug 29 '25	Proposed Sale	19.77	22,117	437,253		Aug 29 04:17 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 18 '25	Sale	18.24	2,805	51,158	23,970	Aug 20 04:13 PM
Kaye Edward M. MD	Director	Aug 18 '25	Sale	18.24	12,126	221,154	153,470	Aug 20 04:12 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 18 '25	Sale	18.24	1,683	30,695	23,948	Aug 20 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 14 '25	Option Exercise	0.00	10,000	0	26,775	Aug 18 08:25 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 14 '25	Option Exercise	0.00	6,000	0	25,631	Aug 18 08:24 PM
Kaye Edward M. MD	Director	Aug 14 '25	Option Exercise	0.00	26,250	0	165,596	Aug 18 08:23 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 13 '25	Sale	15.00	13,712	205,680	19,631	Aug 15 04:31 PM
JONATHAN ALLAN	Officer	Aug 13 '25	Proposed Sale	13.53	13,712	185,523		Aug 13 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 01 '25	Sale	12.82	4,504	57,724	16,775	Aug 05 04:05 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	11.63	4,503	52,379	21,279	Jul 02 04:09 PM
LEVIN ARTHUR A	Director	Jun 30 '25	Option Exercise	0.00	1,210	0	2,420	Jul 02 04:08 PM
BARUCH TICHO	Officer	Jul 01 '25	Proposed Sale	11.35	9,007	102,229		Jul 01 04:27 PM
Skorpios Trust	10% Owner	Jun 04 '25	Sale	10.20	3,000,000	30,600,000	3,906,181	Jun 06 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '25	Sale	10.03	6,471	64,892	25,782	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 02 '25	Sale	10.00	1,745	17,450	32,253	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 02 '25	Sale	10.03	22,790	228,543	33,998	May 05 04:08 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '25	Sale	10.00	3,841	38,410	56,788	May 05 04:08 PM
BARUCH S. TICHO	Officer	May 01 '25	Proposed Sale	9.76	34,847	340,107		May 01 04:45 PM
LEVIN ARTHUR A	Director	Mar 31 '25	Option Exercise	0.00	1,210	0	1,210	Apr 02 04:03 PM

Open in Screener

QTTB

Q32 Bio Inc

Mar 20 • 04:00PM ET

6.68

+0.01 0.15 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT CRSP ARGX BMRN PTCT XENE EDIT MDGL GTX

| Held by: VTI VXF AVUV

Index	-	P/E	2.91	EPS (ttm)	2.30	Insider Own	58.73%	Shs Outstand	12.86M	Perf Week	-2.05%
Market Cap	97.72M	Forward P/E	-	EPS next Y	-3.39	Insider Trans	-0.56%	Shs Float	6.04M	Perf Month	56.44%
Enterprise Value	64.76M	PEG	-	EPS next Q	-0.68	Inst Own	22.81%	Short Float	5.99%	Perf Quarter	131.94%
Income	29.82M	P/S	1.82	EPS this Y	-186.36%	Inst Trans	-4.18%	Short Ratio	1.88	Perf Half Y	283.91%
Sales	53.74M	P/B	2.04	EPS next Y	-62.04%	ROA	38.70%	Short Interest	0.36M	Perf YTD	101.20%
Book/sh	3.27	P/C	2.02	EPS next 5Y	-	ROE	125.06%	52W High	7.80 -14.36%	Perf Year	221.15%
Cash/sh	3.30	P/FCF	-	EPS past 3/5Y	- -	ROIC	59.13%	52W Low	1.35 396.65%	Perf 3Y	-59.22%
Dividend Est.	-	EV/EBITDA	3.75	Sales past 3/5Y	155.87% 81.85%	Gross Margin	99.27%	Volatility	14.87% 13.56%	Perf 5Y	-96.53%
Dividend TTM	-	EV/Sales	1.21	EPS Y/Y TTM	176.79%	Oper. Margin	31.46%	ATR (14)	0.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.85	Sales Y/Y TTM	-100.00%	Profit Margin	55.49%	RSI (14)	65.90	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.85	EPS Q/Q	493.55%	SMA20	21.03%	Beta	-0.02	Target Price	14.33
Payout	0.00%	Debt/Eq	0.37	Sales Q/Q	-	SMA50	46.31%	Rel Volume	1.99	Prev Close	6.67
Employees	24	LT Debt/Eq	0.20	Earnings	Mar 10 BMO	SMA200	132.16%	Avg Volume	192.81K	Price	6.68
IPO	Mar 28, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	632.56% -	Trades		Volume	383,433	Change	0.15%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-25-26	Initiated	H.C. Wainwright	Buy	$13
Feb-11-25	Downgrade	Piper Sandler	Overweight → Neutral	$20 → $4
Feb-11-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$22 → $3
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$95 → $16
Dec-11-24	Downgrade	Raymond James	Strong Buy → Outperform	$90 → $22
Dec-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$68 → $9
Dec-11-24	Downgrade	Guggenheim	Buy → Neutral
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$64
Oct-24-24	Initiated	Raymond James	Strong Buy	$90
Sep-11-24	Initiated	Wells Fargo	Overweight	$95
Jun-17-24	Initiated	Guggenheim	Buy	$100
May-21-24	Initiated	Leerink Partners	Outperform	$54
Apr-11-24	Initiated	Oppenheimer	Outperform	$50
Apr-02-24	Initiated	Piper Sandler	Overweight	$45
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral	$9 → $1.50
Feb-22-22	Reiterated	BTIG Research	Neutral	$35 → $29
Feb-22-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-02-21	Initiated	Stifel	Hold	$14
Dec-14-20	Resumed	H.C. Wainwright	Buy	$30

Show Previous Ratings

Mar-10-26 07:14AM	Q32 Bio: Q4 Earnings Snapshot (Associated Press Finance) +17.45%
06:59AM	Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Mar-01-26 12:34PM	Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab (MarketBeat)
Feb-18-26 06:59AM	Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (PR Newswire) -5.37%
Feb-17-26 06:59AM	Q32 Bio Announces $10.5 Million Registered Direct Offering (PR Newswire) +9.74%
11:28AM	Loading…
Dec-02-25 11:28AM	This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? (Barchart) -10.73%
Dec-01-25 07:00AM	Q32 Bio Sells Complement Inhibitor ADX-097 (PR Newswire) +74.43%
Nov-13-25 07:04AM	Q32 Bio: Q3 Earnings Snapshot (Associated Press Finance) -9.05%
06:59AM	Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Oct-21-25 06:59AM	Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata (PR Newswire) -10.81%
Aug-28-25 06:59AM	Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
Aug-06-25 07:04AM	Q32 Bio: Q2 Earnings Snapshot (Associated Press Finance)
06:59AM	Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Jun-25-25 06:59AM	Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer (PR Newswire)
Jun-24-25 01:06PM	Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary (TipRanks)
07:00AM	Loading…
Jun-23-25 07:00AM	OXB completes acquisition of remaining stake in US subsidiary (GlobeNewswire)
May-08-25 06:59AM	Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Apr-30-25 06:59AM	Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata (PR Newswire)
Apr-16-25 06:59AM	Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata (PR Newswire) -8.19%
Apr-08-25 12:00PM	All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy (Zacks) -5.23%
Mar-11-25 06:59AM	Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -7.77%
Mar-08-25 11:00AM	Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting (PR Newswire)
Feb-28-25 09:00AM	Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting (PR Newswire)
Feb-26-25 06:59AM	Q32 Bio to Participate in Upcoming March Investor Conferences (PR Newswire) -5.26%
Feb-10-25 04:05PM	Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata (PR Newswire) -9.43%
Feb-04-25 04:05PM	Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (PR Newswire) +7.95%
Dec-12-24 07:45AM	Q32 Bio price target lowered to $20 from $80 at Oppenheimer (TipRanks) -28.57%
Dec-11-24 04:11PM	Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment (Investor's Business Daily) -75.62%
09:42AM	Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment (Investor's Business Daily)
Dec-10-24 04:05PM	Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program (PR Newswire) +7.68%
06:59AM	Loading…
Nov-07-24 06:59AM	Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-24 06:59AM	Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (PR Newswire)
Oct-14-24 06:59AM	Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 (PR Newswire)
Aug-29-24 06:59AM	Q32 Bio to Participate in Upcoming September Investor Conferences (PR Newswire)
Jul-09-24 06:59AM	Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis (PR Newswire) +7.89%
Jul-01-24 06:59AM	Q32 Bio Joins Russell 3000 Index (PR Newswire) +5.74%
May-09-24 01:56PM	QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024 (InvestorPlace)
06:59AM	Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Apr-03-24 07:00AM	Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer (PR Newswire)
Mar-18-24 04:30PM	Homology Medicines Declares Distribution to Common Stockholders (GlobeNewswire)
Mar-15-24 09:52PM	FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023 (InvestorPlace)
Mar-01-24 10:48AM	Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:10PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX (GlobeNewswire)
Jan-03-24 04:08PM	Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +5.43%
Nov-17-23 06:40AM	Q32 Bio to merge with Homology Medicines (Pharmaceutical Business Review)
Nov-16-23 12:18PM	Homology enters reverse merger with Q32 Bio (BioPharma Dive) -34.99%
07:05AM	Q32 Bio and Homology Medicines Announce Merger Agreement (PR Newswire)
Nov-14-23 05:02PM	Homology Medicines: Q3 Earnings Snapshot (Associated Press Finance) -13.74%
04:33PM	Homology Medicines Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Aug-14-23 04:20PM	Homology Medicines: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Jul-27-23 04:05PM	Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU (GlobeNewswire) -8.74% +41.49%
04:01PM	Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU (GlobeNewswire)
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey) -5.02%
May-16-23 08:00AM	Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting (GlobeNewswire)
May-11-23 05:35PM	Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Homology Medicines: Q1 Earnings Snapshot (AP Finance)
04:05PM	Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-03-23 07:30AM	Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting (GlobeNewswire) +5.71%
Mar-27-23 05:52AM	BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last? (Zacks)
Mar-15-23 04:01PM	Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting (GlobeNewswire) -5.61%
Mar-09-23 06:45PM	Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -9.46% -8.21%
04:05PM	Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
08:00AM	Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer (GlobeNewswire)
Mar-02-23 07:30AM	Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference (GlobeNewswire) -8.23%
Feb-24-23 05:31AM	Homology Medicines (NASDAQ:FIXX) shareholders have endured a 90% loss from investing in the stock three years ago (Simply Wall St.) -13.12%
Feb-22-23 04:01PM	Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium Meeting (GlobeNewswire) +19.40%
Jan-05-23 09:25AM	Homology Medicines Provides Update From Gene Therapy Trials (Benzinga) +14.62%
Jan-04-23 04:01PM	Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs (GlobeNewswire) +8.33%
Nov-12-22 08:08AM	Homology Medicines Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-10-22 05:45PM	Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +6.38%
04:07PM	Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
Oct-27-22 09:00AM	Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting (GlobeNewswire)
Oct-06-22 08:30AM	Homology Medicines to Participate at Upcoming Conferences (GlobeNewswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire) +5.26%
Sep-08-22 11:05AM	The Petri Dish: Homology gets new CEO amid shakeup; two Boston firms join 'pandemic readiness' lobby (American City Business Journals)
Sep-06-22 04:01PM	Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer (GlobeNewswire)
Aug-17-22 01:05PM	Bedford's Homology Medicine lays off 10 as it puts a program on pause (American City Business Journals)
Aug-16-22 11:52AM	Homology Medicines Pauses Enrollment For Rare Inherited Disorder Study (Benzinga)
Aug-15-22 06:15PM	Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:10PM	Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update (GlobeNewswire)
Aug-12-22 07:46AM	Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder (Benzinga)
Aug-11-22 04:05PM	Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy (GlobeNewswire)
Jul-25-22 09:12AM	Homology Medicines (NASDAQ:FIXX) investors are sitting on a loss of 87% if they invested three years ago (Simply Wall St.)
Jul-05-22 08:30AM	Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver (GlobeNewswire) +5.46%
Jun-29-22 08:00AM	Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU (GlobeNewswire)
Jun-13-22 08:00AM	Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU (GlobeNewswire) -9.77%
Jun-10-22 08:30AM	What Type Of Shareholders Make Up Homology Medicines, Inc.'s (NASDAQ:FIXX) Share Registry? (Simply Wall St.) -6.11%
May-18-22 06:00AM	Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression (GlobeNewswire) -6.62%
May-16-22 06:05PM	Homology Medicines (FIXX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
May-13-22 08:45AM	SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -10.83%
May-02-22 04:56PM	Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting (GlobeNewswire) +5.29%
Apr-21-22 08:30AM	Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President (GlobeNewswire) -7.29%
Mar-23-22 05:45PM	Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -6.32%
04:10PM	Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights (GlobeNewswire)
Mar-10-22 04:01PM	Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica (GlobeNewswire)
Mar-08-22 10:00AM	Here's Why Homology Medicines (FIXX) Looks Ripe for Bottom Fishing (Zacks)
Mar-07-22 09:38AM	Why Homology Medicines (FIXX) Might Surprise This Earnings Season (Zacks)
Mar-03-22 03:00PM	Homology Medicines (FIXX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks) -9.19%

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kalowski Lee	CFO and President	Feb 25 '26	Sale	4.51	3,995	18,035	35,943	Feb 27 07:00 PM
Morrison Jodie Pope	CEO	Feb 25 '26	Sale	4.51	9,896	44,675	89,104	Feb 27 07:00 PM
Violette Shelia M.	Chief Scientific Officer	Feb 25 '26	Sale	4.51	2,815	12,708	55,569	Feb 27 07:00 PM
Morrison Jodie Pope	CEO	Dec 02 '25	Sale	3.46	22,506	77,871	99,000	Dec 04 07:00 PM
Kalowski Lee	CFO and President	Dec 02 '25	Sale	3.46	9,072	31,395	39,938	Dec 04 07:00 PM
JODIE MORRISON	Officer	Dec 02 '25	Proposed Sale	3.46	22,506	77,871		Dec 02 04:29 PM
LEE KALOWSKI	Officer	Dec 02 '25	Proposed Sale	3.46	9,072	31,395		Dec 02 04:05 PM
Morrison Jodie Pope	CEO	Aug 26 '25	Sale	1.80	10,494	18,900	121,506	Aug 28 07:32 PM
Violette Shelia M.	Chief Scientific Officer	Aug 26 '25	Sale	1.80	2,990	5,385	58,384	Aug 28 07:28 PM
Kalowski Lee	CFO and President	Aug 26 '25	Sale	1.80	4,240	7,636	49,010	Aug 28 07:20 PM

STOK

Stoke Therapeutics Inc

QTTB

Q32 Bio Inc

Upgrade your FINVIZ experience